Profound Medical Corp (PROF)

$7.44

-0.01

(-0.13%)

Live

Insights on Profound Medical Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.06M → 1.91M (in $), with an average decrease of 7.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -9.15M → -6.19M (in $), with an average increase of 47.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 90.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 137.1%

Performance

  • $7.40
    $7.60
    $7.44
    downward going graph

    0.54%

    Downside

    Day's Volatility :2.63%

    Upside

    2.11%

    downward going graph
  • $7.11
    $15.49
    $7.44
    downward going graph

    4.44%

    Downside

    52 Weeks Volatility :54.1%

    Upside

    51.97%

    downward going graph

Returns

PeriodProfound Medical CorpSector (Health Care)Index (Russel 2000)
3 Months
-18.76%
-1.0%
0.0%
6 Months
-29.92%
9.6%
0.0%
1 Year
-45.46%
11.0%
0.0%
3 Years
-57.53%
18.5%
-22.6%

Highlights

Market Capitalization
180.0M
Book Value
$1.88
Earnings Per Share (EPS)
-1.29
Wall Street Target Price
12.61
Profit Margin
0.0%
Operating Margin TTM
-391.73%
Return On Assets TTM
-30.83%
Return On Equity TTM
-59.26%
Revenue TTM
7.2M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
2.7%
Gross Profit TTM
3.0M
EBITDA
-28.5M
Diluted Eps TTM
-1.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.19
EPS Estimate Next Year
-0.98
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Profound Medical Corp(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 69.49%

Current $7.44
Target $12.61

Technicals Summary

Sell

Neutral

Buy

Profound Medical Corp is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Profound Medical Corp
Profound Medical Corp
0.47%
-29.92%
-45.46%
-57.53%
-24.6%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Profound Medical Corp
Profound Medical Corp
NA
NA
NA
-1.19
-0.59
-0.31
NA
1.88
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Profound Medical Corp
Profound Medical Corp
Buy
$180.0M
-24.6%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • Gagnon Securities LLC

    6.26%
  • Fidelity International Ltd

    5.53%
  • Letko, Brosseau & Associates Inc.

    5.04%
  • Gagnon Advisors, LLC

    3.06%
  • AIGH Capital Management, LLC

    2.65%
  • Raymond James Finl Svs Advisors, Inc.

    2.56%

Company Information

an inside out approach to prostate ablation profound medical is a canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. profound’s novel technology combines real-time mr imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. it provides a highly precise treatment tailored to patient-specific anatomy and pathology. this method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. the potential of this technology is currently being demonstrated in clinical trials. for more information, visit profoundmedical.com

Organization
Profound Medical Corp
Employees
131
CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Industry
Health Technology

FAQs